Small, low molecular weight compounds which inhibit the cellular activity of P-type Cu-ATPases, ATP7A and/or ATP7B, and pharmaceutical compositions containing the compounds, are described. Methods of using said compounds in the treatment or prevention of any disease in which copper and/or P1B-type heavy-metal ATPases contribute to disease pathology are also described.

Small, low molecular weight compounds which inhibit the cellular activity of P-type Cu-ATPases, ATP7A and/or ATP7B, and pharmaceutical compositions containing the compounds, are described. Methods of using said compounds in the treatment or prevention of any disease in which copper and/or P1B-type heavy-metal ATPases contribute to disease pathology are also described.